Mitochondrial & sleep · Peptide medicine
Also known as elamipretide, Forzinity, MTP-131
A mitochondria-targeting peptide and active ingredient in Forzinity, an FDA-approved product for a narrow Barth syndrome population.[1]
Some human evidence exists, but it is small, early, indirect, or limited to a particular formulation or population.
Reviewed Jul 22, 2026 · U.S.-focused reference profile
Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.
Orientation
Start with identity and research context. Similar names do not establish equivalent products or evidence.
Published research or product contexts. These are not personal indications.
Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.
What is known
Some human evidence exists, but it is small, early, indirect, or limited to a particular formulation or population. This is a description, not a rating or recommendation.
Energy, sleep and healthy-aging research
FDA granted accelerated approval based on a small clinical evidence base in Barth syndrome. The label and FDA trial snapshot describe a pivotal randomized crossover study with twelve participants; confirmatory evidence is required.
Clinical benefit was established under accelerated approval using limited data, and continued approval may depend on confirmatory evidence. Outcomes in other mitochondrial, fatigue, performance, or healthy-aging contexts are not established.
Preclinical mitochondrial studies supported the development rationale. Laboratory and animal findings do not establish clinical benefit outside the labeled rare-disease population.[1]
More human evidence does not automatically transfer to a different product, route, population, or purpose. Limited evidence does not prove no biological activity; it means the relevant clinical question is not established by the reviewed material.
What needs caution
Known published concerns and unanswered questions are kept separate so absence of evidence is never presented as reassurance.
The label describes injection-site reactions and hypersensitivity as important risks. The small exposed population limits detection of uncommon or delayed adverse events.
The cited product label describes risks for a specific approved product and use. It is not a complete guide to every product or individual situation.Source [1]Clinical benefit was established under accelerated approval using limited data, and continued approval may depend on confirmatory evidence. Outcomes in other mitochondrial, fatigue, performance, or healthy-aging contexts are not established.
The answer can change with the product, formulation, route, population, duration, and use being discussed.Source [1]Common effects, important warnings, product-quality concerns, and evidence gaps are different kinds of information. A risk in one product label may not apply to every formulation; an uncertainty proves neither safety nor harm.
Match the product
Form describes the specific product; route describes how it reaches the body. These are sourced descriptions, not instructions.
FDA-approved prescription solution for subcutaneous injection in the labeled Barth syndrome population.
Routes shown apply only to the named published or investigational formulation; they are not instructions for use.
U.S. product context
At least one FDA-approved product exists, but approval applies only to the named product, formulation, route, population, and use in its label.
Status applies to a product, formulation, route, population, and use. It does not apply to a name in the abstract.
Forzinity received FDA accelerated approval to improve muscle strength in patients with Barth syndrome who meet the labeled weight criterion. This approval does not extend to other mitochondrial or wellness uses.
Specific form or route not separately published in this record.View sourceTake it forward
Organize a conversation with a qualified professional without creating a treatment recommendation, dose, or protocol.
Organize an existing plan
PeptideGrid can help you organize a schedule and keep dose records together for a plan you already follow. It does not recommend a dose, schedule, or treatment.
Trace the record
Each source supports the section that cites it; publication does not imply endorsement or suitability.
FORZINITY prescribing information
DailyMed. FORZINITY (elamipretide) prescribing information. Initial U.S. approval 2025.
National Library of Medicine / Stealth BioTherapeutics · Published Dec 12, 2025 · Accessed Jul 22, 2026 · Prescribing information
Open sourceIdentity, human evidence, laboratory and animal findings, risks, uncertainty, and U.S. product status are shown separately. Missing information stays marked as unpublished instead of being inferred.
